A prostate cancer patient with isolated lung metastases: a case report

Wu, Lei; Lei, Lei; Zhu, You‐cai; Du, Ke; Li, Xiaofeng; Chen, Huafei; Wang, Wenxian; Xu, C.

doi:10.21037/tcr.2020.01.19

Cited by 13 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung metastasis is a prevalent type of distant metastasis in PCa patients. [ 32 ] Therefore, we developed a PCa lung metastasis model to assess the effect of the solid systemic anti‐tumor immune response triggered by the “TSD@LSN‐D + L” treatment on the suppression of tumor metastasis. In this study, mice were injected with RM‐1 cells (100 µL, 2×10 5 cells/mouse) in the tail vein on day 10 after the treatments started (Figure 6g).…”

Section: Resultsmentioning

confidence: 99%

A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy

Wang

Jiao

Zhang

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Induction of immunogenic cell death (ICD) in tumor combined with immune checkpoint blockade (ICB) therapy is widely developed to improve the efficacy of cancer immunotherapy. However, the current ICD induced based on apoptosis, i.e., immunogenic apoptosis, is often restricted in immunogenicity owing to the inflammatory quenching that occurs early in apoptosis. Recently, pyroptosis is demonstrated to be a more efficient ICD form, i.e., immunogenic pyroptosis. The cell contents released during pyroptosis can powerfully activate tumor immunogenicity. Herein, first, it is demonstrated that lower doses of epigenetic drug decitabine can increase GSDME expression in prostate cancer (PCa) RM-1 cells and successfully induce an apoptosis-pyroptosis transition after photodynamic therapy (PDT). Subsequently, a microenvironment dual-responsive nano-drug equipped with PD-L1 blocking peptide (TSD@LSN-D) is developed for self-synergistic cancer immunotherapy. The poorly immunogenic RM-1 PCa model confirm that the powerful antitumor immune response evoked by TSD@LSN-D not only can effectively inhibit the primary tumor but also form a long-term immune memory to prevent PCa recurrence and metastasis. To the best of authors' knowledge, this work presents the first concept that promotes the apoptosis-pyroptosis transition after tumor PDT through epigenetic modulation. Furthermore, the powerful combination of immunogenic pyroptosis with ICB opens a new platform for PCa immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy

Wang

Jiao

Zhang

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…In clinical practice, lung metastasis is the more common type of distant metastasis among patients with PCa. [ 30 ] Considering that YBS‐BMS NPs‐RKC‐mediated dual‐pronged PIT, as demonstrated in the above study, can effectively activate the organism's antitumor immunity and facilitate the maintenance of the body's immunological memory, we would like to evaluate whether it could exert an inhibitory effect in the process of PCa lung metastasis. According to the experiment schedule presented in Figure 5i , the PCa lung metastasis model was established.…”

Section: Resultsmentioning

confidence: 99%

Dual‐Pronged Attack: pH‐Driven Membrane‐Anchored NIR Dual‐Type Nano‐Photosensitizer Excites Immunogenic Pyroptosis and Sequester Immune Checkpoint for Enhanced Prostate Cancer Photo‐Immunotherapy

Wang

Gao

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Prostate cancer (PCa) is a frustrating immunogenic “cold” tumor and generally receives unsatisfied immunotherapy outcomes in the clinic. Pyroptosis is an excellent immunogenic cell death form that can effectively activate the antitumor immune response, promote cytotoxic T‐lymphocyte infiltration, and convert tumors from “cold” to “hot.” However, the in vivo application of pyroptosis drugs is seriously limited, and the upregulation of tumor PD‐L1 caused by photo‐immunotherapy further promotes immune escape. Herein, a new nano‐photosensitizer (YBS‐BMS NPs‐RKC) with pH‐response integrating immunogenic pyroptosis induction and immune checkpoint blockade is developed. The pH‐responsive polymer equipped with the cell membrane anchoring peptide RKC is used as the carrier and further encapsulated with the near‐infrared‐activated semiconductor polymer photosensitizer YBS and a PD‐1/PD‐L1 complex small molecule inhibitor BMS‐202. The pH‐driven membrane‐anchoring and pyroptosis activation of YBS‐BMS NPs‐RKC is clearly demonstrated. In vitro and in vivo studies have shown that this dual‐pronged therapy stimulates a powerful antitumor immune response to suppress primary tumor progression and evokes long‐term immune memory to inhibit tumor relapse and metastasis. This work provides an effective self‐synergistic platform for PCa immunotherapy and a new idea for developing more biocompatible photo‐controlled pyroptosis inducers.

show abstract

“…Lung-only metastasis consists of less than 1% of all metastatic prostate cancers. The pathophysiology behind it is not understood well [5]. As such, treatment options can vary from surgical excision of lung lesions to hormonal therapy [6].…”

Section: Discussionmentioning

confidence: 99%

Multifocal Metastatic Spread of Prostate Adenocarcinoma: A Case Report Involving Lung and Brain Infiltration

Bansro

Chhabra

Lee

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Prostate cancer is a prevalent malignancy in males, particularly in older individuals and non-Hispanic Black men. Adenocarcinomas represent most prostate cancers, while other histological types are less common. Metastases from prostate cancer primarily involve bones and lymph nodes, with isolated lung and brain metastases being extremely uncommon. Understanding prostate cancer's clinical characteristics and behavior with atypical metastatic patterns is crucial for accurate diagnosis and optimal treatment strategies. Case Presentation: We present a case of a 60-year-old patient with high-grade Gleason prostate cancer, initially presenting with negative PSA levels. Despite the absence of bone involvement, the patient developed metastases to both the lung and brain, representing an unusual spread pattern. Detailed clinical features, imaging findings, diagnostic workup, and treatment interventions are described to provide a comprehensive understanding of this exceptional case. Conclusion: This case report highlights the rarity and clinical significance of prostate cancer metastases to the lung and brain without bone involvement. Isolated lung and brain metastases from prostate cancer are infrequent occurrences, and their diagnosis and management pose considerable challenges. Clinicians should be aware of these potential metastatic patterns, especially when encountering unusual clinical presentations or imaging findings in prostate cancer patients. Further research and case reports are warranted to enhance our knowledge of these rare metastatic events and optimize treatment approaches for patients with prostate cancer and atypical metastases.

show abstract

A prostate cancer patient with isolated lung metastases: a case report

Cited by 13 publications

References 10 publications

A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy

A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic Immunotherapy

Dual‐Pronged Attack: pH‐Driven Membrane‐Anchored NIR Dual‐Type Nano‐Photosensitizer Excites Immunogenic Pyroptosis and Sequester Immune Checkpoint for Enhanced Prostate Cancer Photo‐Immunotherapy

Multifocal Metastatic Spread of Prostate Adenocarcinoma: A Case Report Involving Lung and Brain Infiltration

Contact Info

Product

Resources

About